Gosset Ownership
Private
Employees
~3
Therapeutic Areas
Stage
Phase 1
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Miist Therapeutics General Information
Phase I trial showed that smokers who used Miist's inhaler eliminated 92% of their cravings in only two minutes, which is a 10X improvement over existing standard of care[6]. The company is preparing for Phase II trials for its smoking cessation technology[6].
Contact Information
Primary Industry
Biotech
Corporate Office
Alameda, California
United States
United States
Drug Pipeline
MST01
Phase 1Key Partnerships
Miist Therapeutics Funding
No funding data available
To view Miist Therapeutics's complete valuation and funding history, request access »